NOVEL REGIMEN FOR CONTROLLED OVARIAN STIMULATION IN MACAQUES

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 重组人促性腺激素(如卵泡刺激素，FSH)在非人类灵长类动物和女性辅助生殖技术中被常规用于促进卵泡发育。由于它们在体内的半衰期相对较短，现有的制剂每天以肌肉或皮下注射的形式给药，通常间隔8-14天，这可能与患者不适、局部刺激和女性依从性下降有关。重组人促性腺激素对非人类灵长类不孕症的研究具有重要意义，它最终会产生中和抗体，从而阻止进一步的刺激方案和有效利用宝贵的动物资源。目前促性腺激素治疗不孕症妇女卵泡刺激或诱导排卵的进展集中在创造体内半衰期更长的重组促性腺激素，或类似促性腺激素。因此，一项临床前研究测试了一种新型促性腺激素在非人灵长类动物模型中刺激卵泡的效果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Recombinant human gonadotropins (e.g., follicle stimulating hormone, FSH) are routinely used to promote follicular development for assisted reproductive technologies in nonhuman primates and women. Because of their relatively short half-life in vivo, the available preparations are administered as daily intramuscular or subcutaneous injections, often for 8-14 day intervals, which can be associated with patient discomfort, local irritation and decreased compliance in women. Of importance to nonhuman primate infertility research, recombinant human gonadotropins elicit eventual production of neutralizing antibodies that precludes further stimulation protocols and efficient use of a valuable animal resource. Current developments in gonadotropin therapy for follicular stimulation or ovulation induction in infertilie women focus on creating recombinant gonadotropins with longer half-lives in vivo, or gonadotropin mimetics. Therefore, a pre-clinical study tested the efficacy of a novel gonadotropin for follicular stimulation in a nonhuman primate model.